A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

This is a first-in-human study testing a new implantable device that delivers chemotherapy (gemcitabine) directly into a pancreatic tumor using a process called iontophoresis — which uses a small electric current to push the drug into the tumor tissue. The goal is to deliver higher doses of chemotherapy right to the cancer while reducing side effects in the rest of the body. **You may be eligible if...** - You have been diagnosed with locally advanced pancreatic cancer that cannot be surgically removed (and has not spread to other organs) - Your cancer was confirmed as non-resectable during exploratory surgery - You have already received standard chemotherapy (FOLFIRINOX or Gem-Abraxane) for this diagnosis - You are in good physical condition (ECOG ≤ 1) **You may NOT be eligible if...** - You have severe or critical pancreatitis - You previously received radiation therapy for your pancreatic cancer - Your cancer has spread beyond the pancreas to other organs - You have a history of significant heart disease - You have metal implants in your body Talk to your doctor to see if this trial is right for you.